Hepatitis C Diagnosis Treatment Market Size

ID: MRFR/MED/1040-HCR

90 Pages

Kinjoll Dey

October 2025

Hepatitis C Diagnosis and Treatment Market Size, Trends and Growth Analysis By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests and others), Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation and others), End User (Hospitals & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2035

Hepatitis C Diagnosis Treatment Market Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Download PDF

Hepatitis C Diagnosis Treatment Size

Hepatitis C Diagnosis Treatment Market Growth Projections and Opportunities

The size of the Hepatitis C diagnosis and treatment market is projected to be USD 80.63 billion by 2030 with a CAGR of 12.4% during the forecast period. The landscape and growth trajectory of the Hepatitis C diagnosis and treatment market are influenced by several market factors. One of the major drivers in this market is the global prevalence of Hepatitis C which is high. This disease is a significant challenge to public health since it has affected millions of people leading to a high demand for effective diagnostic solutions and treatments. Hence, as awareness about HCV increases, and screening intensifies, there will be steady growth in the diagnostics and treatment market Technology developments determine the functioning of the Hepatitis C Diagnosis and Treatment market. Advances in diagnostic tools, as well as therapeutic options, have improved detection methods for virus presence as well as disease management. Through early detection, advanced diagnostics such as nucleic acid testing and serological assays offer opportunities for timely intervention. Similarly, direct-acting antiviral drugs development has changed HCV therapy significantly offering higher cure rates within shorter durations. Regulatory concerns are some key drivers influencing the hepatitis c market dynamics. Regulatory approvals for diagnostic tests, as well as treatment regimens, are stringent due to potential public health impact that may result from them. In conformity with regulatory standards ensures products’ safety plus efficacy thereby giving confidence to medical practitioners alongside patients who use them. With approved products having wider acceptance hence gaining a lot of credibility in the markets than ever before; this therefore shows how regulatory pathway acts shaping competitive landscape. Public awareness and acceptance are two key factors affecting hepatitis c dynamics within the market. Raising awareness about importance of early diagnosis, availability of effective treatments along with consequences associated with untreated Hepatitis C is necessary. Market has been positively impacted through public health campaigns alongside education efforts which have resulted to an increase in screening rates as well as treatment seeking behavior.

Hepatitis C Diagnosis Treatment Market Size Graph

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

The Global Hepatitis C Diagnosis and Treatment Market is projected to grow significantly from 46.5 USD Billion in 2024 to 117.4 USD Billion by 2035.

Key Market Trends & Highlights

Hepatitis C Diagnosis and Treatment Key Trends and Highlights

The market is expected to experience a compound annual growth rate (CAGR) of 8.78 percent from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 117.4 USD Billion, indicating robust growth potential.
In 2024, the market is valued at 46.5 USD Billion, reflecting the current demand for hepatitis C diagnosis and treatment solutions.
Growing adoption of innovative treatment modalities due to increasing prevalence of hepatitis C is a major market driver.

Hepatitis C Diagnosis Treatment Market

CAGR

8.78%

Market Size & Forecast

2024 Market Size	46.5 (USD Billion)
2035 Market Size	117.4 (USD Billion)
CAGR (2025-2035)	8.78%
Largest Regional Market Share in 2024	latin_america)

Major Players

Hoffmann-La Roche Ltd, Vertex Pharmaceuticals Incorporated, Gilead Sciences, Inc., AbbVie Inc., Novartis Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Abbott, Beckman Coulter, Inc., Siemens Medical Solutions USA, Inc., MedMira Inc., GlaxoSmithKline PLC, DiaSorin SpA, Qiagen, bioMérieux SA, Hologic, Inc., Bio-Rad Laboratories, Inc.

Market Trends

The ongoing advancements in diagnostic technologies and antiviral therapies are poised to reshape the landscape of Hepatitis C management, potentially enhancing patient outcomes and reducing transmission rates.

Centers for Disease Control and Prevention (CDC)

Hepatitis C Diagnosis Treatment Market Market Drivers

Market Growth Projections

Emergence of Direct-Acting Antivirals

The emergence of direct-acting antivirals (DAAs) has revolutionized the treatment landscape for Hepatitis C, significantly impacting the Global Hepatitis C Diagnosis and Treatment Market Industry. DAAs offer high cure rates and shorter treatment durations compared to traditional therapies, making them a preferred choice for patients and healthcare providers. The introduction of these innovative therapies has not only improved patient outcomes but also increased the overall treatment uptake. As a result, the market is witnessing a shift towards more effective treatment modalities, which is expected to drive growth in the coming years. The ongoing development of new DAAs further indicates a promising future for Hepatitis C treatment.

Advancements in Diagnostic Technologies

Technological advancements in diagnostic methods are transforming the landscape of the Global Hepatitis C Diagnosis and Treatment Market Industry. Innovations such as point-of-care testing and non-invasive diagnostic tools enhance the speed and accuracy of Hepatitis C detection. For instance, the development of rapid antibody tests and advanced molecular techniques allows for timely diagnosis, which is crucial for effective treatment initiation. These advancements not only improve patient outcomes but also facilitate broader screening initiatives, potentially reducing the burden of the disease. As the market evolves, the integration of these technologies is expected to contribute significantly to the anticipated growth, with projections indicating a market size of 117.4 USD Billion by 2035.

Rising Global Prevalence of Hepatitis C

The increasing prevalence of Hepatitis C globally serves as a primary driver for the Global Hepatitis C Diagnosis and Treatment Market Industry. As of 2024, approximately 71 million individuals are estimated to be living with chronic Hepatitis C worldwide. This growing patient population necessitates enhanced diagnostic and treatment solutions, thereby propelling market growth. The World Health Organization emphasizes the importance of early detection and effective treatment, which further underscores the need for innovative diagnostic technologies and antiviral therapies. Consequently, the market is projected to expand significantly, with a valuation of 46.5 USD Billion in 2024, reflecting the urgent demand for comprehensive Hepatitis C management.

Growing Awareness and Education Programs

The rising awareness regarding Hepatitis C and its implications is a crucial driver for the Global Hepatitis C Diagnosis and Treatment Market Industry. Educational programs aimed at informing the public about the risks, transmission, and treatment options for Hepatitis C are gaining momentum. Organizations and health authorities are actively promoting awareness campaigns that encourage individuals to seek testing and treatment. This heightened awareness is likely to lead to an increase in diagnosed cases, thereby driving demand for effective treatment options. As more individuals become informed about their health, the market is expected to experience substantial growth, aligning with the overall trend of increasing healthcare engagement.

Increased Government Initiatives and Funding

Government initiatives aimed at combating Hepatitis C are pivotal in driving the Global Hepatitis C Diagnosis and Treatment Market Industry. Many countries are implementing national strategies to eliminate Hepatitis C, which includes increased funding for screening programs and access to treatment. For example, the U.S. Centers for Disease Control and Prevention has launched campaigns to raise awareness and promote testing among high-risk populations. Such initiatives not only enhance public health outcomes but also stimulate market growth by increasing the demand for diagnostic and therapeutic solutions. The commitment to eradicate Hepatitis C is likely to sustain the market's upward trajectory, with a projected CAGR of 8.78% from 2025 to 2035.

Market Segment Insights

Regional Insights

Key Companies in the Hepatitis C Diagnosis Treatment Market market include

Industry Developments

In India, Abbott introduced "LiverHealth," a project to make it easier to diagnose liver function and promote awareness about hepatitis C.

The market is consolidated, with Gilead Sciences, Inc. accounting for roughly 80.1 percent of the market share, with the majority of revenue coming from the sales of the medications Harvoni and Sovaldi. Bristol-Myers Squibb Company and AbbVie Inc. are the other main participants.

Future Outlook

Hepatitis C Diagnosis Treatment Market Future Outlook

The Hepatitis C Diagnosis and Treatment Market is projected to grow at 8.78% CAGR from 2024 to 2035, driven by advancements in diagnostic technologies, increased awareness, and enhanced treatment options.

New opportunities lie in:

Developing point-of-care testing solutions to improve accessibility in remote areas.
Investing in telemedicine platforms for remote patient monitoring and consultations.
Forming strategic partnerships with biotech firms for innovative drug development.

By 2035, the market is expected to achieve substantial growth, reflecting advancements in diagnosis and treatment methodologies.

Market Segmentation

Report Scope

Attribute/Metric	Details
Market Size 2023	44.2 (USD Billion)
Market Size 2024	46.55 (USD Billion)
Market Size 2032	82.34 (USD Billion)
Compound Annual Growth Rate (CAGR)	12.56 % (2024 - 2032)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2023
Market Forecast Period	2024 - 2032
Historical Data	2019 - 2023
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), Gilead Sciences, Inc. (US), AbbVie Inc. (US), GlaxoSmithKline PLC (UK), Novartis Pharmaceuticals Corporation (Switzerland), Bristol-Myers Squibb Company (US), Abbott (US), Beckman Coulter, Inc. (US), Siemens Medical Solutions USA, Inc. (Germany), MedMira Inc. (Canada), DiaSorin SpA (Italy), Qiagen (Germany), bioMérieux SA (France), Hologic, Inc. (US), and Bio-Rad Laboratories, Inc. (US)
Key Market Opportunities	The Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from hepatitis C. \r\nAccording to the WHO, 10 million people in Africa suffer from chronic viral hepatitis C
Key Market Drivers	Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from hepatitis C and rising number of initiatives taken by governments as well as private institutes to create awareness regarding hepatitis C

Market Highlights

Author

Kinjoll Dey

Research Analyst Level I

She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Latest Comments

John Doe

john@example.com

This is a great article! Really helped me understand the topic better.

Posted on July 23, 2025, 10:15 AM

Jane Smith

jane@domain.com

Thanks for sharing this. I’ve bookmarked it for later reference.

Posted on July 22, 2025, 7:45 PM

View All

FAQs

At what CAGR is the Hepatitis C diagnosis and treatment market projected to grow in the forecast period (2024-2032)?

Hepatitis C diagnosis and treatment market is projected to grow at approximately 12.56% CAGR during the assessment period (2024-2032).

What are the major tailwinds pushing the growth of the Hepatitis C diagnosis and treatment market?

high prevalence and increasing awareness about the diseases are major tailwinds pushing the growth of the Hepatitis C diagnosis and treatment market.

What are the key growth impeders of the Hepatitis C diagnosis and treatment market?

Stringent government regulations and the availability of alternate treatment options are major growth impeders for the Hepatitis C diagnosis and treatment market.

Which region holds the largest share in the Hepatitis C diagnosis and treatment market?

North America holds the largest share in the Hepatitis C diagnosis and treatment market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the Hepatitis C diagnosis and treatment market?

Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (US), Vertex Pharmaceuticals Incorporated (US), AbbVie Inc. (US), Novartis Pharmaceuticals Corporation (Switzerland), GlaxoSmithKline PLC (UK), Bristol-Myers Squibb Company (US), Beckman Coulter, Inc. (US), Abbott (US), Siemens Medical Solutions USA, Inc. (Germany), DiaSorin SpA (Italy), MedMira Inc. (Canada), Qiagen (Germany), Hologic, Inc. (US), bioMérieux SA (France), and Bio-Rad Laboratories, Inc. (US), are some of the top players operating in the Hepatitis C diagnosis and treatment market.

Table of Contents
REPORT PROLOGUE
MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS
6.1. Overview
6.2. Liver Function Tests
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Liver Biopsy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Blood Tests
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT
7.1. Overview
7.2. Antiviral Medications
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Immuno-Modulators
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Liver Transplantation
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Diagnostic Centers
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Hepatitis C Diagnosis and Treatment Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of the Number of Developments in the Global Hepatitis C Diagnosis and Treatment Market
10.7. Key Developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2020
10.8.2. Major Players R&D Expenditure 2020
10.9. Major Players Capital Market Ratio
COMPANY PROFILES
11.1. F. Hoffmann-La Roche Ltd
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Vertex Pharmaceuticals Incorporated
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Gilead Sciences, Inc.
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. AbbVie Inc.
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. GlaxoSmithKline plc
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Novartis Pharmaceuticals Corporation
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Bristol-Myers Squibb Company
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Abbott.
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Beckman Coulter, Inc.
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Siemens Medical Solutions USA, Inc.
11.10.1. Company Overview
11.10.2. Product Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. MedMira Inc.
11.11.1. Company Overview
11.11.2. Product Overview
11.11.3. Financial Overview
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. DiaSorin SpA
11.12.1. Company Overview
11.12.2. Product Overview
11.12.3. Financial Overview
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Qiagen
11.13.1. Company Overview
11.13.2. Product Overview
11.13.3. Financial Overview
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. bioMérieux SA
11.14.1. Company Overview
11.14.2. Product Overview
11.14.3. Financial Overview
11.14.4. Key Developments
11.14.5. SWOT Analysis
11.14.6. Key Strategies
11.15. Hologic, Inc.
11.15.1. Company Overview
11.15.2. Product Overview
11.15.3. Financial Overview
11.15.4. Key Developments
11.15.5. SWOT Analysis
11.15.6. Key Strategies
11.16. Bio-Rad Laboratories, Inc.
11.16.1. Company Overview
11.16.2. Product Overview
11.16.3. Financial Overview
11.16.4. Key Developments
11.16.5. SWOT Analysis
11.16.6. Key Strategies
11.17. Others
APPENDIX
12.1. References
12.2. Related Reports
List of Tables and Figures
1. TABLE 1 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SYNOPSIS, 2020-2027
2. TABLE 2 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
3. TABLE 3 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
4. TABLE 4 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
5. TABLE 5 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
6. TABLE 6 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
7. TABLE 7 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
8. TABLE 8 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
9. TABLE 9 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
10. TABLE 10 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
11. TABLE 11 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
12. TABLE 12 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
13. TABLE 13 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
14. TABLE 14 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
15. TABLE 15 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
16. TABLE 16 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
17. TABLE 17 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
18. TABLE 18 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
19. TABLE 19 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
20. TABLE 20 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
21. TABLE 21 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
22. TABLE 22 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
23. TABLE 23 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
24. TABLE 24 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
25. TABLE 25 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
26. TABLE 26 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
27. TABLE 27 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
28. TABLE 28 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
29. TABLE 29 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
30. TABLE 30 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
31. TABLE 31 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
32. TABLE 32 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
33. TABLE 33 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
34. FIGURE 1 RESEARCH PROCESS
35. FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET
36. FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET
37. FIGURE 4 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY DIAGNOSIS, 2020 (%)
38. FIGURE 5 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
39. FIGURE 6 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY END USER, 2020 (%)
40. FIGURE 7 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)
41. FIGURE 7 AMERICAS: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2020 (%)
42. FIGURE 8 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
43. FIGURE 9 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)
44. FIGURE 10 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
45. FIGURE 11 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
46. FIGURE 12 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
47. FIGURE 13 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
48. FIGURE 14 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS
49. FIGURE 15 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE
50. FIGURE 16 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE
51. FIGURE 17 VERTEX PHARMACEUTICALS INCORPORATED: KEY FINANCIALS
52. FIGURE 18 VERTEX PHARMACEUTICALS INCORPORATED: SEGMENTAL REVENUE
53. FIGURE 19 VERTEX PHARMACEUTICALS INCORPORATED: REGIONAL REVENUE
54. FIGURE 20 GILEAD SCIENCES, INC.: KEY FINANCIALS
55. FIGURE 21 GILEAD SCIENCES, INC.: SEGMENTAL REVENUE
56. FIGURE 22 GILEAD SCIENCES, INC.: REGIONAL REVENUE
57. FIGURE 23 ABBVIE INC.: KEY FINANCIALS
58. FIGURE 24 ABBVIE INC.: SEGMENTAL REVENUE
59. FIGURE 25 ABBVIE INC.: REGIONAL REVENUE
60. FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS
61. FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
62. FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
63. FIGURE 29 NOVARTIS PHARMACEUTICALS CORPORATION: KEY FINANCIALS
64. FIGURE 30 NOVARTIS PHARMACEUTICALS CORPORATION: SEGMENTAL REVENUE
65. FIGURE 31 NOVARTIS PHARMACEUTICALS CORPORATION: REGIONAL REVENUE
66. FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
67. FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
68. FIGURE 34 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE
69. FIGURE 35 ABBOTT.: KEY FINANCIALS
70. FIGURE 36 ABBOTT.: SEGMENTAL REVENUE
71. FIGURE 37 ABBOTT.: REGIONAL REVENUE
72. FIGURE 38 BECKMAN COULTER, INC.: KEY FINANCIALS
73. FIGURE 39 BECKMAN COULTER, INC.: SEGMENTAL REVENUE
74. FIGURE 40 BECKMAN COULTER, INC.: REGIONAL REVENUE
75. FIGURE 41 SIEMENS MEDICAL SOLUTIONS USA, INC.: KEY FINANCIALS
76. FIGURE 42 SIEMENS MEDICAL SOLUTIONS USA, INC.: SEGMENTAL REVENUE
77. FIGURE 43 SIEMENS MEDICAL SOLUTIONS USA, INC.: REGIONAL REVENUE
78. FIGURE 44 MEDMIRA INC.: KEY FINANCIALS
79. FIGURE 45 MEDMIRA INC.: SEGMENTAL REVENUE
80. FIGURE 46 MEDMIRA INC.: REGIONAL REVENUE
81. FIGURE 47 DIASORIN S.P.A.: KEY FINANCIALS
82. FIGURE 48 DIASORIN S.P.A.: SEGMENTAL REVENUE
83. FIGURE 49 DIASORIN S.P.A.: REGIONAL REVENUE
84. FIGURE 50 QIAGEN: KEY FINANCIALS
85. FIGURE 51 QIAGEN: SEGMENTAL REVENUE
86. FIGURE 52 QIAGEN: REGIONAL REVENUE
87. FIGURE 53 BIOMÉRIEUX SA: KEY FINANCIALS
88. FIGURE 54 BIOMÉRIEUX SA: SEGMENTAL REVENUE
89. FIGURE 55 BIOMÉRIEUX SA: REGIONAL REVENUE
90. FIGURE 56 HOLOGIC, INC.: KEY FINANCIALS
91. FIGURE 57 HOLOGIC, INC.: SEGMENTAL REVENUE
92. FIGURE 58 HOLOGIC, INC.: REGIONAL REVENUE
93. FIGURE 59 BIO-RAD LABORATORIES, INC.: KEY FINANCIALS
94. FIGURE 60 BIO-RAD LABORATORIES, INC.: SEGMENTAL REVENUE
95. FIGURE 61 BIO-RAD LABORATORIES, INC.: REGIONAL REVENUE

Hepatitis C Diagnosis and Treatment Market Segmentation

Market Segmentation Overview

Detailed segmentation data will be available in the full report
Comprehensive analysis by multiple parameters
Regional and country-level breakdowns
Market size forecasts by segment

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027